Italia markets open in 4 hours 44 minutes

DBV Technologies S.A. (0QAJ.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
4,7347+0,0967 (+2,08%)
Alla chiusura: 05:19PM GMT
Schermo intero
Chiusura precedente4,6380
Aperto4,6420
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno4,6160 - 4,8100
Intervallo di 52 settimane4,6160 - 4,8100
Volume1.795
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,38
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

    AMF Regulated InformationMontrouge, France, January 23, 2023 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2022: 149,793 DBV Tec

  • GlobeNewswire

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market: NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights12/31/202294,137,145Total gross of voting rights: 94,137,145Total net* of voting rights: 93,966,891 * Total net = total number of voting rights attached to shares – shares withou

  • GlobeNewswire

    DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

    Montrouge, France, December 23, 2022 DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 and topline results anticipated in 1H 2025Company reiterates that cash on-hand is sufficient to fund operations through VITESSE topline data DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, tod